We usually administer dual antiplatelet therapy in various combinations to a post PCI patient. Some of them are on chronic anticoagulant therapy for stroke prevention. Some of them may have relatively higher bleeding risk. How do you plan your antiplatelet regime to such patients without compromising bleeding risk and risk of stent thrombosis?
Hi Kamal,
there was an article in the Deutsche Aerzteblatt about this topic recently.
https://www.aerzteblatt.de/cme/artikel?id=219271
You will find a link to an English version on the right hand side of the homepage in about two weeks time, I guess...or you try and use deepl for translation.
Calculate his bleeding risk/thrombotic risk
Ranging from triple therapy (ASA+Clopidogrel+warfraine) for one month then warfarine plus clopidogrel onwards for 6month/one year then warfraine alone after one year for high bleeding low thrombosis risk patients or
It will be triple for three months then dual (warfarine+clopidogrel) for 6 month/one year then warfarine one
Thank you very much. Would you please refer an article? @ Amir Khalifa.
- Badges
- Science topic
- Similar topics
- Mathematical Sciences
- Statistics
- Statistical Software
- SPSS